Secondary prevention with antiplatelet medications in patients with antiphospholipid antibody-related stroke
Authors:
Open Access
- 1 March 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Abstract
Clinical guidelines recommend warfarin for patients with antiphospholipid syndrome (APS) and ischemic stroke; however, robust evidence is lacking. We investigated the clinical benefits of different categories of antithrombotic medications in ischemic stroke patients positive for antiphospholipid antibodies (aPLs) in real-world practice. We reviewed data from patients with ischemic stroke or transient ischemic attack who tested positive for aPLs. Based on their secondary preventive antithrombotic medications, patients were classified into antiplatelet and anticoagulant categories, and further into warfarin, single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT), and direct oral anticoagulant groups. The outcome of interest was a composite of recurrent thrombosis and major bleeding events. Time-varying Cox proportional hazards model was used. Among 167 eligible patients, 28 experienced composite outcome events over 601.1 person-years. SAPT and DAPT demonstrated clinical benefits over warfarin (SAPT vs. warfarin, adjusted hazard ratio [95% confidence intervals], 0.24 [0.07–0.83]; DAPT vs. warfarin, 0.25 [0.08–0.81]). Notably, DAPT was advantageous regarding major bleeding (DAPT vs. warfarin, 0.10 [0.02–0.47]), while the risk of recurrent thrombotic events was comparable between the antiplatelet and warfarin groups. Antiplatelet therapy may be a safe and effective alternative to warfarin for secondary prevention of aPL- and APS-related stroke. Further prospective validation is required.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2021R1A2B5B01002360)
This publication has 30 references indexed in Scilit:
- Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndromeInternational Journal of Medical Sciences, 2010
- Effect of Study Setting on Anticoagulation ControlChest, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic StrokeJAMA, 2004
- Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patientsArthritis & Rheumatism, 2002
- Cerebrovascular Ischemic Events With High Positive Anticardiolipin AntibodiesStroke, 1998
- A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis.1997
- The Management of Thrombosis in the Antiphospholipid-Antibody SyndromeNew England Journal of Medicine, 1995
- Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 PatientsAnnals of Internal Medicine, 1992